Mathias Ehrich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SAN DIEGO & REHOVOT, Israel, April 04, 2024--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes. The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10

/PRNewswire/ -- Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and...

/PRNewswire/ -- Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and...

San Diego, CA (PRWEB) May 04, 2022 -- Juno Diagnostics™, Inc. (JunoDx™), a women’s health company focused on improving equitable access to prenatal care led

The round was led by the Perceptive Xontogeny Venture (PXV) Fund. The company intends to use the funds to support clinical validation studies, product development, and commercial launch of its product offerings for noninvasive prenatal testing (NIPT). Led by Dirk van den Boom, Founder and Chief Executive Officer, Mathias Ehrich M.D., Chief Scientific Officer, and Jim Chauvapun, Chief Operations Officer, Juno Diagnostics is developing genetic testing solutions to improve access to vital health information. The company’s lead product is an NIPT solution that simplifies sample collection and ...